Thus, RAS testing should be executed in all patients with CRC, and include NRAS exons 2, 3, 4 and KRAS exons 2, 3, 4 at least.327 BRAF testing also could help to select the therapy option and predict the prognosis. This evidence concerns the gene BRAF and colorectal carcinoma.